EPHA2 and hepatocellular carcinoma: The study used CRISPR-Cas9-mediated inhibition of EPHA2 expression in the mouse liver and showed a significant reduction in tumor burden compared to the control, indicating that EPHA2 may be a potential therapeutic target for HCC.